Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab

Figure 1

Kaplan-Meier curves for median progression free survival (PFS) of colorectal cancer patients treated with irinotecan and cetuximab showing phosphorylated AKT expression (-------) and without phosphorylated AKT expression (———) in either primary tumours (A, 2.4 months vs. 6.5 months, p = 0.0006) or metastases (B, 2.3 months vs. 9.2 months, p = < 0.0001).

Back to article page